A Distinct Dexamethasone-Dependent Gene Expression Profile in the Lungs of COVID-19 Patients. (27th May 2022)

• Record Type: Journal Article
• Authors: Fahnøe, Ulrik; Ronit, Andreas; Berg, Ronan M G; Jørgensen, Sofie E; Mogensen, Trine H; Underwood, Alexander P; Scheel, Troels K H; Bukh, Jens; Plovsing, Ronni R
• Is Part Of: Journal of infectious diseases. Volume 226:Number 12(2022)
• Page Start: 2137
• Page End: 2141
• Publication Date: 2022-05-27
• Subjects: acute respiratory distress syndrome -- bronchoalveolar lavage fluid -- coronavirus disease 2019 -- inflammation -- interferon stimulated genes -- transcriptome profiling; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac218
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: The effects of dexamethasone (DXM) treatment on pulmonary immunity in COVID-19–associated acute respiratory distress syndrome (CARDS) remain insufficiently understood. We performed transcriptomic RNA-seq analysis of bronchoalveolar lavage fluid from 20 mechanically ventilated patients: 12 with CARDS (with or without DXM) and 8 non–COVID-19 critically ill controls. CARDS with DXM was characterized by upregulation of genes related to B-cell and complement pathway activation, antigen presentation, phagocytosis, and FC-γ receptor signaling. Most interferon-stimulated genes were upregulated in CARDS, particularly in CARDS without DXM. In conclusion, DXM treatment was not associated with regulation of proinflammatory pathways in CARDS but with regulation of other local immune responses. Clinical Trials Registration . NCT04354584. Abstract : A distinct dexamethasone-dependent transcriptomic signature was detected in the lungs of mechanically ventilated COVID-19 patients.